Inmagene Biopharmaceuticals

Merged

Designed to be different: Developing a potential best-in-class anti-OX40 treatment with features that matter to patients | Imagene

Business Model
B2B
Total Funding
$121.0M
Last Round
$100.0M Series CMay 2021
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Inmagene Biopharmaceuticals was a clinical-stage biopharmaceutical company focused on developing novel therapeutics for immunological, autoimmune, and inflammatory diseases. The company's lead program was an anti-OX40 monoclonal antibody targeting immune pathways implicated in conditions such as atopic dermatitis and alopecia areata. In July 2025, Inmagene completed its merger with Ikena Oncology, with the combined entity subsequently rebranded and operating as ImageneBio, Inc.

Summary

Inmagene Biopharmaceuticals is a Biotech company. It has raised $121.0M in total across 2 rounds, most recently a $100.0M Series C round in May 2021. Investors include HighLight Capital, Vertex Ventures China and Deep Track Capital.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Secondary MarketSecondary MarketJul 2025

Sign up to see all 3 events

Funding: Series B through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Inmagene Biopharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/inmagene-biopharmaceuticals"><img src="https://indexed.vc/api/badge/company/inmagene-biopharmaceuticals" alt="Inmagene Biopharmaceuticals on Indexed.vc" width="260" height="76" /></a>